Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Jennifer Friedmann, Michelino De Laurentiis et al.|Journal of Clinical Oncology|2024Cited by 163
Abstract RF02-03: Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)Komal Jhaveri, Sherene Loi, Fabrice André et al.|Cancer Research|2024Cited by 12